Lincoln Pharma eyes export boost after patenting its ‘painless’ malaria injection

Ahmedabad-based Lincoln Pharmaceuticals said it developed a painless form of malaria injection and has also received a patent in India for the same.

It said it expects to increase its exports of anti-malarial treatments by 70-80% thanks to the invention.

At present, the Arteether anti-malarial injection available in market are in 3 ml and 2 ml ampoules form. As a result, the injection is “very painful for a long time.”

Patient will have to take this injection at east for a period of three days to control malaria, the company said.

Lincoln Pharma’s R&D Research team has developed a painless injection with compressed dosage form by reducing the size of the drug by up to 50% volume.

“This new “Arteether injection” developed by our company is available in 1 ml only. Due to this new innovation, the patient will get faster relief and (it will be) painless,” it said.

“The results of this new “Arteether injection” are far better than the other existing dosages form are available in the market,” it added.

The company has received Patent No 258915 for the invention, it said.


Lincoln Pharma said the invention will help it increase its presence in Africa, already a big market for the company.

The majority of African countries use similar injections to control malaria.

The total anti-malarial market in African Countries are estimated Rs 586 cr, said the company.

Lincoln Pharma is exporting nearly Rs 50 Crores anti-malarial products to African countries.

“With introduction of this new “Arteether injection” in African countries, company expect to increase additional Rs 35 Crore to Rs 40 crore revenue in the coming years,” it said.